{"name":"Tarsus Pharmaceuticals, Inc.","slug":"tarsus-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Lotilaner ophthalmic solution, 0.25%","genericName":"Lotilaner ophthalmic solution, 0.25%","slug":"lotilaner-ophthalmic-solution-0-25","indication":"Demodex blepharitis","status":"marketed"},{"name":"TP-03 Vehicle","genericName":"TP-03 Vehicle","slug":"tp-03-vehicle","indication":"Ocular surface disease (specific indication under investigation in Phase 3)","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TP-03","genericName":"TP-03","slug":"tp-03","indication":"Dry eye disease","status":"phase_3"}]}],"pipeline":[{"name":"TP-03","genericName":"TP-03","slug":"tp-03","phase":"phase_3","mechanism":"TP-03 is a monoclonal antibody targeting the CD40 receptor.","indications":["Dry eye disease"],"catalyst":""},{"name":"Lotilaner ophthalmic solution, 0.25%","genericName":"Lotilaner ophthalmic solution, 0.25%","slug":"lotilaner-ophthalmic-solution-0-25","phase":"marketed","mechanism":"Lotilaner is a non-selective sigma receptor antagonist that reduces ocular surface inflammation and irritation associated with Demodex mites.","indications":["Demodex blepharitis","Ocular rosacea"],"catalyst":""},{"name":"TP-03 Vehicle","genericName":"TP-03 Vehicle","slug":"tp-03-vehicle","phase":"phase_3","mechanism":"TP-03 Vehicle is a topical ophthalmic formulation designed to deliver active pharmaceutical ingredients to the ocular surface.","indications":["Ocular surface disease (specific indication under investigation in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOcGtqWWEwNDJtbGFSeGhNbDc5YzU3RkJMTTVURFRtVkFpSWZPbVNKaU9xMjVtdG10aVExTG05SUtRZWh5MkVTTVlSRGhoVy11VkI5ZlJFejdJQnVZYVBNWDdWeE03RzBObC1sdVJzWnB4X25QYVJvSkdLdUZVOWNqYzVxYTV5VzdtVzgwWDAyNGxfc2V2bUp4Y21LQQ?oc=5","date":"2026-03-24","type":"pipeline","source":"Yahoo Finance","summary":"Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - Yahoo Finance","headline":"Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPN0ZHbXJTRnVxaVBzWEJSWEd4VWFDUTY1dTNBQTlobUJBMmhhdzB4WG1sMHEyYktDM0JMUTJmQ05SbWhfZ3VhX0N1QnlOUUNDN1p6VkpBZXdJNnVSRV95NXdsckd1YVJPbHR4cDFrVVNEN1J2b0JEc3R3WUNCcmJoR3ZJVlF2NjdPVGVpc2Nqc1oxUXBaMU1UaU1OaFdudnMtblV6WXVXY3ZrV05vcWxOdmNVZzBRSm1hXzBhZkxn?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"China clears first Demodex blepharitis treatment for 40 million people - Stock Titan","headline":"China clears first Demodex blepharitis treatment for 40 million people","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxNY2tVbkp4RVVTTEtDejRqX1RuTVcxMmhVMFJoUHUycW1pM2F6Qm0yUkRqWWxUVHEtRl9HLXdIY3FXdVl6V3M1NTVubWhvaTBFZjlnWlVWYTZBZXhEVEpxMW5hVmtqY0Nxd2ZtcDJ4TnpfZm54SGlod3d3VlVXZWZzQ25PTXFsUkhyd1JuVDMzY1lIdTB2MzJmczl3MlNtN3I1clR1V0tkZHRMT2ozdzBOekxUZ1h4SDFQNnpWQ0dDQ3NUYjJrY256WmZJVGRSMWpUM0VBSVNNd2ZuZHZXaWRhZUZ2QVNkQW54SmxpV050c3pBYnUwY2tHR2ZpTjkzeXdjV3pucy04eUhIYWtoS0oyRWJEQmtWLUdUS0I3WklweW0xbEtmRE5FY3FsWk5jN3VOOG5ZR25INFRZTEZxRFlsemNn?oc=5","date":"2026-03-23","type":"regulatory","source":"GlobeNewswire","summary":"TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in - GlobeNewswire","headline":"TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5qSjNLeVVGMlBENENFVTJETlR4Vk1Ya1ctQ1l5UEFwai1NZUVDWFFHYzFGQU8xU2NiQzFoVFA1MlY5cXVHRWxoWVJRU0FRSGs2M0EzaHp0VW1uYVVWUUHSAWNBVV95cUxObkJaVW1oemxsNVgyMWVJMzF5WTdULTV3N0d6SURlRzBYRjhHY2tMMlc2Zm0zT0k0RmZrM3pmS0xFZGRoM1VkeEVaYlBReGdydkZmV01yMzkzQnpKOWQyNGh0X1E?oc=5","date":"2026-03-23","type":"regulatory","source":"Bitget","summary":"TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus - Bitget","headline":"TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNN19sc19LQ1V5OUlGZHkzZURZajVnU25ydndsdkMyTW1pNFQzN1o5djlqaENzNkYwRkJDeDVYOXRrb2YzSDNxdUJEeEhmcy1DRU4xTE5ScUdHZEJHdHZSRGtDT2U0Tzl6VHEyb2VNWjVfNW9zZUhodjFRc3FNTnI2M2RKWWRPcVplUGdmRVBpMnNkMUs4NEd5WEpmcmJ2d3Focl9QblVwcVNRVlFnX0RWdXZfVVNFVW9tQVlZ?oc=5","date":"2026-03-19","type":"pipeline","source":"Investing.com","summary":"Farrow Jeffrey S of Tarsus Pharma sells $439k in shares - Investing.com","headline":"Farrow Jeffrey S of Tarsus Pharma sells $439k in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNNm1MV1BLcGlNZ1BuS2FKVDBGZGQyVUwzSHE3RmQyX3psc2VabEZsZDlja01DeEp3dmpmOVEyOGdaMDRUY3pTVnBNYUY2Z1ZEdzliSlhoZ25QTXh2cmxVSUlqNDZ6czFVR1VrMHg2Q3hPcWdWQjJ0LW9Ud0pUQ3Naakpwcnh1enlUcXAxMm1DTTJhSFd4Rk9YcTdMdGIwdVhIYVB5S2hPLVFIQVVPaGNyRHM5bGxEbFZqbzNv?oc=5","date":"2026-03-19","type":"pipeline","source":"Investing.com","summary":"Tarsus Pharma general counsel Wahl sells $850k in stock - Investing.com","headline":"Tarsus Pharma general counsel Wahl sells $850k in stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNb3dJOGh4VXA3ZVMxbm13UnNaSUl4ZkpQNE5FOVB1WDZfd0EyeFVRRjZPZkpFREhZc2hxbUZSTU42b1hRdU5TNjg5VTFLaWtaaW1oa3d1ZXdRYVNFbmk1S1hfalhjb1ZKMGVzMDJBSzdmZ1NPc1JpcUlILVhoRUROQzAtV3pRV19ZUmtJN1BrWXFzQXlLaGNDVFA2eEg5dWtRcG9yOF9IblpWeVZtYWtHS3BTQkMtQU0yVk01X0UtbTA?oc=5","date":"2026-03-19","type":"pipeline","source":"Investing.com","summary":"Tarsus Pharma COO Neervannan Seshadri sells $772k in shares - Investing.com","headline":"Tarsus Pharma COO Neervannan Seshadri sells $772k in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQcG1qT1k5UUlwVWoySHB4dmw5UlEtX1h0QTVVQTk4VmN6RDRLc3dxaDJURnBJTXFQX2pvRHpaYzZXMkRET3o3TG9pVDVPZ3UxNTR3S092TTlDWllFMjlvV0xlZVNXWGIyb1M1WnVpd2VRTTQ1MzZhNmhtVWU5dUJzejFIQVRpc0FFX2dxNnUtandBaXJwT0lNb2hhb1dXQWtGRFJLMFA1WHFlWkY5MjhwR05mMzc0WE5nb2Etbng4c1ZhbkJ1cGRId282UEEwbEhCX3R5dG9hV3VEYkJjWl96cGFfSGVyNDdzTVBiRHJYMFBIXzVDZENJbWhmWQ?oc=5","date":"2026-02-18","type":"pipeline","source":"BioSpace","summary":"Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors - BioSpace","headline":"Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPN2Q4bUd5RWFzeTV1ZXdXRHo2aVBqd3RoRFRBeF91MUR2aWNNdWRTbkwwZ3d1cFdka0JzWTNGS01NQ3RXZVAtaG9WRnV4QnFDQWswRTdrZENyQVdXSTJxWS1EZ0tDWVVyLXhaRklQeHhUQmpsbTZaNUlCNzgteWxuSXNVZmJlMW1MRkRsODlFNFdBNDluUDZJdDZtdUZjblNzcDk2RHJxR29xZw?oc=5","date":"2025-11-04","type":"pipeline","source":"BioSpace","summary":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces - BioSpace","headline":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQemdoXzNYTkJpc1NIcDJrY2lUcDFUNTk5MHM1bzY0aW1ZTUd2RzYzV3A1MFZIVFJvMEhxMjlTdFdBYVZCZUc5WXNmZ0o3QVJKZ3Q0eWhyQjRDUE92eHZ4TFBSZFRkbHU4QmdXZ3gyZVU5NnhNOWpqeE51S3RaLXNkdHhHNGdGbXZxMWhIU3UyN3QzUUhwZHkzLUxlUGkwVmhfOEtPNko5VjJrT2Jwa2xr?oc=5","date":"2025-09-26","type":"pipeline","source":"seekingalpha.com","summary":"Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off (NASDAQ:TARS) - seekingalpha.com","headline":"Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off (NASDAQ:TARS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPb2pERDdoQUVFMnNuaHVOQ0FEOWZhQW9LckZhTTQ5VGdIbElRd21ldGhKeFFXeWZTNzNSeU9acTRtc3g1c2VxR2pOaTN1NVVRT2VOaE9oNURzOWI2dkxyQ3BHY08ta3Q2NC1GOUlqNnRmWWFHOVU0eHl3MXdSVWxaUGV4U2hUTWNCbzlZSWpkbnNwSFJuc0RVOG1WdmFiR1g3?oc=5","date":"2025-05-12","type":"pipeline","source":"seekingalpha.com","summary":"Tarsus Pharmaceuticals: The \"Get Big Fast\" Approach Could Pay Off (NASDAQ:TARS) - seekingalpha.com","headline":"Tarsus Pharmaceuticals: The \"Get Big Fast\" Approach Could Pay Off (NASDAQ:TARS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxObFhXLS1Ca1hjR0ZtdHRwMVhRLWNPSS16Y3lOUWxtSnNWSTF4cVRJWThZb2VLWVNOSE5WY3VnaTk0bWlLRWV0bGZvcVRIS1UzNUdQRjVtUE1YcXNnaHNFTnBzaXVZRzhBMzAyN3RFVThla0NRYnBYSFBlUGFVemRkdExXaUZjTEd0dTBBMA?oc=5","date":"2025-02-13","type":"pipeline","source":"Life Science Leader","summary":"Where Are They Now? Tarsus Pharmaceuticals - Life Science Leader","headline":"Where Are They Now? Tarsus Pharmaceuticals","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}